Catalyst Event
Eli Lilly and Co (LLY) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
3/19/2026, 12:00:00 AM
Announced positive topline results from the TRANSCEND-T2D-1 Phase 3 trial for its investigational drug retatrutide, which showed significant reductions in A1C and body weight for adults with type 2 diabetes; a price impact of over 10% is estimated.
Korean Translation
제2형 당뇨병 환자를 대상으로 한 임상 3상 시험(TRANSCEND-T2D-1)에서 연구용 의약품 레타트루타이드가 당화혈색소(A1C) 및 체중을 유의미하게 감소시키는 긍정적인 탑라인 결과를 발표함. 주요 임상 성공으로 10% 이상의 주가 영향이 예상됨.
Related Recent Events
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled; a price impact of at least 1% is expected.
4/30/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Q1 2026 earnings release is scheduled.
4/21/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Other
New target action date for the FDA's decision on oral obesity drug orforglipron, following an extension of the review period announced on January 15, 2026, scheduled; a price impact of at least 1% is expected.
4/10/2026, 12:00:00 AM
Caris Life Sciences Inc (CAI) · Other
The company is scheduled to present five studies at the 2026 USCAP Annual Meeting from 2026-03-21 to 2026-03-26 scheduled.
3/21/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Other
Appeals court ruling on whistleblower lawsuit regarding 340B program overcharging allegations scheduled for March 18, 2026; moderate impact expected from potential legal liabilities, scheduled.
3/18/2026, 12:00:00 AM
Adaptive Biotechnologies Corp (ADPT) · Other
President and COO Julie Rubinstein sold 57,180 shares between March 16 and March 18, 2026, for a total of approximately $762,000 under a pre-arranged 10b5-1 trading plan.
3/18/2026, 12:00:00 AM